JAGSNPHARMNSEJagsonpal Pharmaceuticals Limited· PharmaceuticalsMediumNeutral
Announced Tue, 30 Dec · 16:52 IST

Jagsonpal Pharmaceuticals Limited has informed the Exchange about Action(s) taken or orders passed

Regulatory & Legal View source PDF

JAGSNPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Jagsonpal Pharmaceuticals has received an order from the Deputy Commissioner of State Tax (SGST), Gurugram (East), Haryana, dated December 29, 2025, demanding a total of about INR 1.52 crore for FY 2021-22. The break-up is INR 84.89 lakh as tax, INR 58.60 lakh as interest, and INR 8.49 lakh as penalty. The demand relates to mismatches between input tax credit claimed in GSTR-2A and GSTR-3B returns and the tax liability shown in e-waybills versus GSTR-1. The company has stated it will file an appeal before the Appellate Authority along with the required pre-deposit and does not expect any material impact on its financials or operations.

Likely market impact

This is a routine tax dispute under GST law and not a SEBI, court, or NCLT action. The demanded amount (~INR 1.52 crore) is small relative to a listed pharma company and the company plans to appeal, so near-term impact on share price or operations should be limited unless the appeal fails.